Navigation Links
Indolent in Medical News

Study shows that maintenance rituximab is useful for advanced indolent lymphoma

A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. ...

Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

TREANDA Receives Second Indication this Year; Data Demonstrate High, Durable Response Rates for Patients with indolent NHL Who Have Progressed Following a Rituximab-Containing Regimen FRAZER, Pa., Nov. 3 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that the U.S. F...

Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

TREANDA Receives Second Indication this Year; Data Demonstrate High, Durable Response Rates for Patients with indolent NHL Who Have Progressed Following a Rituximab-Containing Regimen FRAZER, Pa., Oct. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announce...

Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

...ived its second approval in October 2008 for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within si...cated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive ...

Gene fusion discovery may lead to improved prostate cancer test

...ly significant prostate cancer." "Our work has a long-term goal of achieving a test that distinguishes clinically significant prostate cancer from indolent disease that does not require additional treatment. With better diagnosis, we will be able to treat cancer patients with individualized therapies -- o...

A new approach to prostate cancer detection

... clarify a diagnosis. But even when a biopsy reveals cancer, it often remains unclear whether the cancer is aggressive and at risk of spreading, or indolent and likely to stay put. Rather than looking for genes or proteins, Dr. Arun Sreekumar and his team of the University of Michigan measured the levels o...

PSA Testing: What Should Men Do?

...atally. Many grow so slowly that they are no danger to life. But no test currently available can tell the difference between a life-threatening and an indolent prostate cancer. On the other hand, aggressive treatment of prostate cancer carries its own dangers, which include possible incontinence and impote...

2 Studies Conflict Over Value of Prostate Cancer Screening

...elmann, professor of oncology at Columbia University Medical Center in New York City. "We're pretty good at identifying very aggressive tumors or very indolent tumors, but there is a large grey area." "That kind of advance might be just around the corner," Berg said. "I do think we are making strides towar...

Early detection of second breast cancers halves women's risk of death

...length-time bias into account when quantifying the impact of early, asymptomatic detection of breast cancer. This is important because slow-growing or indolent cancers have a much smaller probability of proving fatal, and this group of women will tend to be over-represented in the early-detected cancers, bias...

New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkin's Lymphomas

... Horowitz noted. He also noted that these lymphomas are nearly always indolent or slow growing. Relapses are common regardless of the treatment; however t...ment option to reflect the FDA's approval of the agents in the treatment of indolent NHL and Chronic Lymphocytic Leukemia (CLL). Extensive revisions were m...
Indolent in Medical Technology

Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL

Overview of 11 peer review publications presented in 'Future Oncology' SEATTLE, June 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reports a summary of peer reviewed publications spanning preclinical, Phase I and Phase II clinical studies wit...

Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma

Zevalin(R) First-Line Indolent (FIT) Phase III Clinical Trial results published in Journal of Clinical Oncology SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the...

TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

Final Data from Pivotal Study Presented at 49th American Society of Hematology Meeting FRAZER, Pa., Dec. 10 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that in a pivotal study of patients with indolent non-Hodgkin's lymphoma (NHL), whose ...

Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)

Fast Track-Designated Study Approved Under FDA Special Protocol Assessment Process Could Expand Indication to Indolent NHL SEATTLE, Sept. 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTAX) today announced the launch of its phase III clinical trial, know...

Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent

Phase II Investigational Trial Published in CANCER: the Journal of the American Cancer Society SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTAX) announced today that results of a phase II clinical study, published in the jou...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

....1 months) compared to rituximab alone in relapsed indolent NHL Phase II; AZA I06- Pixantrone plus f...gh CR/CRu (70%) and ORR (89%) in multiple relapsed indolent NHL Cell Therapeutics, Inc. ...TI's pixantrone clinical studies in aggressive and indolent NHL including follow-up data and subgroup analyses...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

...) for Injection, which is approved in the United States for the treatment of chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen and ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...single-arm, multicenter Phase II study was designed to assess the efficacy and safety of everolimus in patients with relapsed/refractory aggressive or indolent NHL or Hodgkin's disease whose disease progressed despite prior treatment. Patients had received a median of four prior therapies (between one and 15 ...

AUA Guideline: Full Kidney Removal Not Necessary for All Kidney Tumors

... has increased in frequency and is now a common clinical scenario for the practicing urologist. Of these tumors, 20 percent are benign, 60 percent are indolent kidney cancer, and only about 20 percent are potentially aggressive kidney cancer at the time of diagnosis. Kidney cancer is the most lethal of the c...

A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations

...he development of new clinical tests that can differentiate between those men at greatest need for aggressive prostate cancer treatment and those with indolent forms of the disease who can be well managed without invasive treatment. This statement is approved by the following U.S.-based prostate cancer...
Indolent in Medical Dictionary

Actinomycosis

... Actinomycosis is a chronic bacterial disease. Localized swelling with ... Actinomycosis ... Abdominal actinomycosis is the most covert and indolent ... Actinomycosis also sometimes affects the lungs, appendix, or the pelvic region, ... Actinomycosis also occurs in horses, cattle, swine, an...
Indolent in Biological News

Research could lead to new non-antibiotic drugs to counter hospital infections

...s appeared on the worms before they died. "These findings provide novel insight into the mechanisms by which P. aeruginosa is able to shift from indolent colonizer to a lethal pathogen when present in the intestinal tract of a stressed host," said Alexander Zaborin, lead author of the study and a resear...

Pair of microRNA molecules controls major oncogene in most common leukemia

...h expression of these miRNAs correlates with low expression of TCL1, in the indolent form of cancer that is less likely to progress. A low level of miR-29 and m...e researchers studied TCL1 expression and miRNA expression in 23 samples of indolent B-CLL, 25 samples of aggressive B-CLL, and 32 samples of B-CLL exhibiting a...

AIDS-related cognitive impairment exists in two separate forms

...ive extra therapy after surgery - or whether some of these patients have an indolent disease that does not even require surgery. Most patients with colorectal c...trong enough predictor of a good prognosis at the stage of biopsy, men with indolent cancer may not need surgery or radiation at all," she said. "We know man...

Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers

...ive extra therapy after surgery - or whether some of these patients have an indolent disease that does not even require surgery. Most patients with colorectal c...trong enough predictor of a good prognosis at the stage of biopsy, men with indolent cancer may not need surgery or radiation at all," she said. "We know man...

BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins

... Biovest is now enrolling patients in a pivotal Phase 3 trial to test BiovaxID against follicular non-Hodgkin's lymphoma (NHL). Follicular NHL is an indolent (slow-growing) form of lymphoma not considered curable with existing therapies. The impressive findings from the Phase 2 clinical trial using BiovaxID...
Indolent in Biological Technology

Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

FRAZER, Pa., Dec. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of TREANDA(R) (bendamustine HCl) for Injection for the treatment of patients with i...

Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit

...oducts: TREANDA, which is approved in the United States for the treatment of chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen and ...

Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million

...er, 2007 and having the foresight to bring the first line consolidation for indolent NHL data to the FDA for potential label expansion in the front line consoli... forms - aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institu...

Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009

...w of 2008 Key Accomplishments: Entered into an agreement with Bayer Schering Pharma to gain access to its positive phase III Zevalin First-line indolent Trial (FIT) data for submission to the FDA in connection with the Zevalin sBLA. Successful pre-sBLA meeting with FDA and submission of sBLA for...

FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review

...ecember 2007. CTI gained access to the First-line indolent Trial (FIT) data through an agreement with Bayer S...e duration. About the Phase III First-line indolent Trial (FIT) The multinational, randomized phase III First-line indolent Trial (FIT) evaluated the benefit and safety of a ...

Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug

...a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. The American C...icals. "ZEVALIN is safe and effective in treating indolent NHL. Although approved by the FDA in 2002, its po...rently receiving ZEVALIN treatments for refractory indolent NHL, generating approximately $15 million in annua...

Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting

...a monotherapy, in the following indications: acute myeloid leukemia, non-small cell lung cancer, hepatocarcinoma, and chronic lymphocytic leukemia and indolent B-cell lymphomas. The latter study is being conducted with the financial and scientific support of the Leukemia and Lymphoma Society through their inn...

High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma

...at drains fluid from the body. NHL can be broadly classified into two main forms -- aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in...

Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy

...esponse duration. About the Phase III First-line indolent Trial (FIT) The multinational, randomized phase III First-line indolent Trial (FIT) evaluated the benefit and safety of a ...a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to th...

FDA Meeting Provides Green Light for Cell Therapeutics Submission of Supplemental Filing for Zevalin(R) Label Expansion

...Drug Administration (FDA) data from the First-line indolent Trial (FIT) would be sufficient to support a submi...esponse duration. About the Phase III First-line indolent (FIT) Trial The multinational, randomized phase III First-line indolent Trial (FIT) evaluated the benefit and safety of a ...
Indolent in Biological Dictionary

Transformation

.... ... Diffuse Large B-cell lymphoma - so-called histologic transformation to a diffuse growth pattern ... Transformation should be suspected in indolent lymphoma ... Senior defense officials are getting a glimpse of the latest in unmanned systems ... Army General Urgers Faster Fielding of Unmanned V...
Other Tags
(Date:12/21/2014)... California (PRWEB) December 21, 2014 ... have announced a new intro plugin for Final Cut ... animate pictures, videos, logos, and more with absolute ease.” ... given our users the tools needed to easily animate ... allows Final Cut Pro X users to animate pictures, ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering ... has recently shown its new engineered bamboo flooring collection, ... flooring models. , BambooIndustry.com’s customers come from many countries ... According to the CEO of the company, the global ... the past few years, and the demand for eco-friendly ...
(Date:12/20/2014)... Dress company LunaDress has recently announced its ... Christmas Sale, offering big discounts on all of its special ... idea to own a perfect wedding gown. If you have ... then come to LunaDress. Many different wedding dress styles and ... website now and enjoy the current special offer, up to ...
(Date:12/20/2014)... 2014 The Doctor’s Office Urgent Care of ... part of a decade. They’ve treated over 40,000 patients ... healthcare alternative to the Paramus area. , ... additions to their staff of top-notch board certified physicians: Christine ... These new doctors will work tirelessly to carry ...
(Date:12/20/2014)... 20, 2014 Recently, AngelWeddingDress.com has introduced ... ”) for the coming Christmas. In the promotion, all ... off. , “We have something special for the women ... holiday season. Moreover, our new collections of 2015 dresses ... offered now at greatly discounted prices. Visit our website ...
Breaking Medicine News(10 mins):Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
Other Contents